Novo to Fight Back With New Products to Regain Ground in ChinaBy
Newer Novo drugs expected to hit market within couple of years
About 114 million Chinese are estimated to have diabetes
Novo Nordisk A/S, the world’s largest maker of insulin, expects to roll out new diabetes treatments in China within a couple of years, helping the company take on competition that’s eroded its share of the local market.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.